Amwell Beats Q2 2026 Earnings and Revenue Estimates

Key Facts

1Amwell reported an EPS of -$0.59, beating the consensus estimate of -$0.86.

2Q2 revenue reached $52.05 million, surpassing the estimated $49.87 million.

3The company narrowed its operating loss by 53% to $9.6 million, ending with $196 million in cash.

Amid a strategic shift toward AI-powered healthcare infrastructure, Amwell reported robust financial results for the second quarter of 2026. The company posted an earnings per share (EPS) loss of -$0.59, significantly better than the consensus estimate of -$0.86. Quarterly revenue reached $52.05 million, surpassing the anticipated $49.87 million, despite a year-over-year decline in total revenue figures.

According to analyst data, the company narrowed its operating loss by 53% to $9.6 million, supported by a cash position of $196 million and zero debt. This improvement reflects Amwell's focus on subscription-based revenue models, which now account for over half of total income at $25.7 million. These results come as the firm aims to break even on operations and cash flow by the fourth quarter.

Based on available market data, updated closing prices for AMWL were unavailable at the time of this report, requiring investors to monitor liquidity levels at the next market open. Regarding the economic calendar, there are no upcoming catalysts directly impacting the telehealth sector, though broader market sentiment may react to global GDP and consumer confidence data released in late July 2026.

Sources:

Financial Modeling Prep

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.